Introduction
One-third of the world's population has been latently infected with M. tuberculosis 1 and 5-10% of those with latent infection is expected to develop clinical tuberculosis (TB) at a later stage. 2 Thus, it would be of great value to have available prophylactic and therapeutic vaccines that could confer improved protection to the noninfected and infected populations, respectively. Current control programs against TB include chemotherapy and BCG vaccination. 3 Although chemotherapy, notably directly observed therapy, short-course (DOTS), has dramatically increased the effectiveness of TB control with a cure rate of around 85%, 4, 5 it is currently available to only 12% of patients with active disease worldwide, because it is expensive and has significant side effects. Moreover, current DOTS requires 6-9 months for an effective cure, since it is difficult to kill dormant bacteria with chemotherapeutic drugs. 6 BCG has been used worldwide and appears to be effective in protecting young children from disseminated TB, but not adults. 7 BCG is also ineffective against the endogenous reactivation of M. tuberculosis. 7 Therefore, it is of considerable importance for the control of TB to develop new drugs or therapeutic vaccines that prevent more completely the reactivation of TB in addition to drugs capable of more efficient cure via shortened periods of therapy. In TB lesions, macrophages infected with M. tuberculosis are surrounded by activated T cells. 8 Both CD4 + and CD8 + T cells have been shown to lyse infected macrophages expressing mycobacterial antigens. [9] [10] [11] In particular, an analysis of the immunological mechanism in a mouse model suggested that the induction of Th1 immune response, including antigen-specific CD8 + / CD4 À /CD44 high memory type cytotoxic T cells producing IFN-g, is required for TB therapeutic vaccine efficacy. 12 These cellular immune responses also appear to be required for maximally effective antituberculosis immunity in humans. 13, 14 Recent understanding of the immunopathogenesis of TB suggests the possible application of adjunctive immunotherapy for TB treatment. Accordingly, DNA vaccination has been actively pursued, since it is known to establish cellular immune responses, including cytotoxic T-lymphocyte (CTL) and Th1 responses. As new prophylactic TB vaccines, DNA vaccines appeared to be promising in animal models. Prophylactic DNA vaccines expressing M. tuberculosis antigens or cytokines are of particular interest, because of their efficiency and long-lasting effect in animal TB models. For example, prophylactic DNA vaccines expressing various M. tuberculosis antigens, including Ag85A, [15] [16] [17] Ag85B, 17, 18 65 kDa heat shock protein, 19, 20 and PstS-3 21 , were found to be effective at limiting the growth of M. tuberculosis in mice. In contrast, there has been little evidence that DNA vaccines are useful as therapeutic vaccines against TB. The immunotherapeutic inoculation of DNA vaccine expressing Ag85A has been previously shown to have a protective effect when given prior to bacterial challenge, without any apparent effect on the course of lung infection. 22 Thus, to enhance the therapeutic effect of DNA vaccines, DNA vaccines combined with conventional chemotherapy were recently evaluated as a therapeutic TB vaccine regimen. However, DNA vaccine expressing several M. tuberculosis antigens when given after chemotherapy did not prevent reactivation of disease. 23 Interestingly, Lowrie et al recently reported that the vaccination of plasmid DNA expressing hsp65 after chemotherapy proved effective at preventing the reactivation of M. tuberculosis. 24, 25 These results suggest that immunotherapy designed to boost the efficiency of the immune system in infected patients could be a valuable adjunct to antibacterial chemotherapy.
In the present report, we evaluated whether IL-12 mutant (IL-12N220L) DNA or Ag85A DNA vaccine administered during 3-month chemotherapy course has an impact on preventing the reactivation of M. tuberculosis in a latent model of TB. IL-12N220L is N-glycosylation mutant at Asn220 of mouse IL-12p40, and leads to a reduced secretion of the p40 subunit, a natural antagonist of IL-12. 26 Coimmunization of IL-12N220L DNA with hepatitis C virus (HCV) E2 DNA was reported to significantly enhance long-term E2-specific CTL response and IFN-g-producing CD8
+ T-cell response compared to wild-type IL-12 DNA. 26 Here, we found that the Ag85A or IL-12N220L DNA vaccination when combined with chemotherapy reduced M. tuberculosis reactivation, compared with chemotherapy alone. In addition, Ag85A DNA vaccine showed a better therapeutic effect than IL-12N220L DNA vaccine, suggesting the potential use of Ag85A DNA vaccine in combination with chemotherapy as a therapeutic agent against TB for the prevention of TB reactivation as well as for the effective cure of TB in humans. 27 In contrast, the treatment of infected mice with INH and PZA for 6 months prevented the appearance of detectable bacterial numbers either at 30 or 42 weeks postinfection (2 or 14 weeks after the completion of 6-month chemotherapy) ( Table 1 ). In addition, even at 80 weeks postinfection (52 weeks after the completion of 6-month chemotherapy), no reactivation of M. tuberculosis was found in the lungs or spleens, indicating that chemotherapy over 6 months prevented M. tuberculosis reactivation.
Results

Establishment of a latent infection model
Antigen-specific IFN-g production by IL-12N220L or Ag85A DNA vaccine
To examine the immune responses produced by DNA vaccines injected during chemotherapy, mice were intramuscularly inoculated with IL-12N220L or Ag85A DNA vaccine three times (4 weeks intervals) during a 3-month chemotherapy course from 4 weeks postinfection, according to the schedule represented in Figure 1 . IFN-g is known to be essential in the control of experimental tuberculosis in mice 28, 29 and to be the first identified human immunologic factor essential for resistance against mycobacterial infection.
30 So, we believed it would be of interest to determine the level of antigenspecific IFN-g production by splenocytes of mice immunized with DNA vaccines. At 30 weeks postinfection, splenocytes of immunized mice were stimulated with culture filtrate (CF) or Ag85A protein, and the levels of IFN-g production were determined using ELISA (Figures 3a and b) . When INH and PZA were not given to infected mice, IFN-g production specific for CF or Ag85A was below the detectable level (data not shown). However, in mice treated with INH and PZA, a detectable level of CF-or Ag85A-specific IFN-g production was observed, indicating that host Th1 immune responses were generated by INH and PZA treatment after bacterial infection (Figures 3a and b) . This observation is consistent with previous studies, namely that this chemotherapy in TB patients leads to an increase of IFNg production specific for different antigenic peptides. 31, 32 Interestingly, mice immunized with empty plasmid DNA during chemotherapy course showed a higher level of IFN-g production in response to both CF and Ag85A protein than the control mice given chemotherapy alone (Figures 3a and b) , suggesting that the CpG motifs in DNA vector could work as an inducer of Th1 immune response, as previously reported. 33 Expectedly, mice immunized with IL-12N220L DNA showed a higher level of IFN-g production in response to CF than mice immunized with empty plasmid DNA or Ag85A DNA (Figure 3a , Po0.03 in both cases). In addition, IL-12N220L DNA vaccine showed an increased level of Ag85A-specific IFN-g production compared with the empty plasmid DNA (Figure 3b , Po0.04). These results show that the antigen-specific T helper immune response generated after TB infection was further biased toward the Th1 type by IL-12N220L DNA immunization. In contrast, Ag85A DNA-immunized mice showed a significantly higher level of IFN-g production in response to Ag85A protein than empty plasmid DNA or IL-12N220L DNA-immunized mice (Figure 3b , Po0.01 or Po0.04, respectively), but not to CF (Figure 3a) , indicating that Ag85A-specific Th1 immune response may be enhanced by Ag85A DNA immunization.
Therapeutic effects of IL-12N220L DNA or Ag85A DNA vaccines Bacterial numbers were determined in the organs of mice at 30 weeks postinfection (14 weeks after the completion of 3-month chemotherapy: Table 1 and Figures 4a and b) . Mice treated with INH and PZA showed the highest reactivation rates in both lungs and spleens (80 and 100%, respectively), as mentioned above. Interestingly, (Table 1 and Figures 4a  and b) . Surprisingly, no viable organism was recovered from the lungs of all five mice immunized with Ag85A DNA (Table 1 and Figure 4a ). In the spleens, M. tuberculosis was recovered in only one (20%) of five mice (Table 1 and Figure 4b ). These results indicate that DNA vaccine expressing IL-12N220L or Ag85A in combination with INH and PZA chemotherapy can be used as a genetic adjuvant to prevent the reactivation of M. tuberculosis. Bacterial numbers were also determined in the tissues of mice at 42 weeks postinfection (26 weeks after the completion of 3-month chemotherapy), in order to examine the long-term effects of DNA vaccines on the reactivation of M. tuberculosis (Table 1 and Figures 4c and  d) . In control mice treated with only INH and PZA, M. tuberculosis was recovered in the lungs and spleens of four (80%) and three (60%) of five mice, respectively. Mice given empty plasmid DNA showed a 60% reactivation rate in both lungs and spleens. In contrast, viable M. tuberculosis was found in the lungs and spleens of two (40%) of five mice immunized with IL-12N220L DNA. The mice immunized with Ag85A DNA showed the lowest M. tuberculosis reactivation rate in both lungs and spleens (20%).
When the reactivation rates at 30 and 42 weeks postinfection were combined, a significant reduction in the reactivation of M. tuberculosis was observed in the lungs of the mice immunized with IL-12N220L DNA (Po0.05, w 2 test) or Ag85A DNA (Po0.01, w 2 test) ( Table  1 ). In the spleens, mice immunized with Ag85A DNA showed a significant level of protection (Po0.05), whereas the protection rate in mice immunized with IL-12N220L DNA was not statistically meaningful (Table  1) . Interestingly, the rates of reactivation in both lungs and spleens appeared to be inversely correlated with the Ag85A-specific IFN-g production level, but not with the CF-specific IFN-g production level, which demonstrates that Ag85A-specific Th1 immunity has a more prominent role in protection from M. tuberculosis.
Discussion
Immunotherapy including DNA vaccine in conjunction with conventional chemotherapy against M. tuberculosis has been tried recently by Lowrie et al. 24, 25 They showed that mice immunized three times with hsp65 DNA vaccine, started 2 weeks after the completion of INH/ PZA treatment for 3 months, significantly decreased M. tuberculosis reactivation compared to those given chemotherapy alone. When compared with the results of Lowrie et al, our results showed that chemotherapy combined with immunotherapy including IL-12N220L or Ag85A DNA vaccine could also be effective for the prevention of TB reactivation, and suggest the potential of IL-12N220L or Ag85 DNA vaccines as therapeutic agents. In addition, our study using an aerosol infection model rather than an intravenous infection model provides information more closely related to the clinical situation, since human tuberculosis is naturally transmitted by the inhalation of small numbers of bacteria. Furthermore, our regimen of simultaneously involving concurrent chemotherapy and DNA vaccine would be more clinically useful than a regimen involving sequential DNA vaccination and chemotherapy. However, the efficacies of immune response induction and the therapeutic activity of these two different regimens remain to be determined.
IFN-g production from the PBMCs of patients with active pulmonary TB is clearly reduced in response to purified protein derivative (PPD), compared with that of DNA vaccines against tuberculosis S-J Ha et al healthy tuberculosis reactors (HTR), suggesting a relation between low IFN-g levels and the lack of protection. 34, 35 Many attempts have been made to elucidate the natures of the TB antigens involved in stimulating protective IFN-g production. Actually, it was reported that IFN-g production specific for antigens of M. tuberculosis such as Ag85A, 35, 36 Ag85B, 35, 37 MTB41, 38 and ESAT-6 39 dramatically reduces in patients with active TB but not in HTR, suggesting that these antigens may be candidate protective antigens. 8 In the case of Ag85A, it was also demonstrated that the reduced production of IFN-g in response to Ag85A was significantly restored in PBMCs 35 after anti-TB chemotherapy in patients with active disease, suggesting that Ag85A-specific IFN-g response might be involved in the clinical phenotype and immunopathogenesis of human active pulmonary TB. Moreover, mouse immunization experiments have shown that vaccination with DNA encoding Ag85A could generate strong CD4 + T-cell-mediated Th1 and CD8 + T-cell-mediated CTL responses and be responsible for improved protection against challenge by virulent M. tuberculosis in animal models. [15] [16] [17] In the present study, we demonstrate for the first time that Ag85A DNA vaccine could also be effective at reducing the reactivation of established M. tuberculosis (Table 1 and Figure 4 ). Rates of reactivation in both lungs and spleens were found to be inversely correlated with the Ag85A-specific IFN-g production level, but not with the CFspecific IFN-g level (Figures 3a and b) , indicating that Ag85A-specific Th1 immunity may be more important than Th1 immune response specific for CF in terms of protection against M. tuberculosis reactivation. These results suggest that Ag85A could play a role as a protective antigen in a therapeutic mode. It is worthwhile to note that chemotherapy alone induced a detectable level of Ag85A-specific IFN-g production, but that Ag85A DNA vaccination during chemotherapy significantly enhanced its production (Figure 3b ). Thus, it is possible that DNA vaccination encoding Ag85A might boost the Ag85A-specific T cells generated during chemotherapy course or newly generate the Ag85A-specific T cells. These T cells would generate an efficient 
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Th1 immune response, including IFN-g production, and eventually inhibit the growth of M. tuberculosis.
Since the importance of IL-12 in the control of mycobacterial infections has been well documented, [40] [41] [42] [43] many attempts have been made to use IL-12 for immunotherapy against M. tuberculosis. In humans, a low dose of IL-12 cured a patient with IFN-g-refractory pulmonary M. abscessus, and successfully induced a sputum negative conversion. 44 In mice, treatment with recombinant IL-12 protein combined with antimycobacterial drugs resulted in decreased bacterial numbers, compared with the administration of the cytokine or drug alone in M. avium-infected SCID mice and immunocompetent mice. 45 Our study demonstrates that IL-12N220L DNA vaccine combined with chemotherapy effectively reduced M. tuberculosis reactivation ( Table 1) , and that this correlates well with a high level of IFN-g production by the splenocytes of mice immunized with IL-12N220L DNA upon in vitro stimulation with CF or Ag85A protein (Figures 3a and b) . We attribute this to both the IL-12-mediated improved priming of immune cells and the enhancement of Th1 immune responses specific for M. tuberculosis antigens, which were produced and trapped in tissues before starting the INH and PZA treatment. When the therapeutic activity of IL-12N220L DNA against TB was compared with its wildtype IL-12 DNA, the wild-type IL-12 DNA was found to be less effective in terms of reducing bacterial numbers and antigen-specific IFN-g production at both 30 and 42 weeks postinfection in the same model (our unpublished data). We previously demonstrated that IL-12N220L DNA, as a prophylactic vaccine, can significantly protect immunized mice against tumor challenge after DNA immunization, compared with wild-type IL-12 DNA immunization. 26 Based on these two studies, we suggest that IL-12N220L DNA could be used as a more effective vaccine than wild-type IL-12 DNA in both therapeutic and prophylactic modes.
Although conventional chemotherapy has shown high cure rates in TB patients, it requires long-term therapy of more than 6 months to achieve cure. As shown in Table 1 and Figure 4 , IL-12N220L or Ag85 DNA immunization, as immunotherapies, combined with chemotherapy over 3 months showed a stronger therapeutic effect than chemotherapy alone; however, it does not appear to be superior to chemotherapy over 6 months. Thus, we suggest the possibility that immunotherapy including DNA vaccine combined with chemotherapy might shorten the period of conventional chemotherapy. However, to determine an optimal combined regimen sufficient to confer a similar or superior therapeutic activity to conventional 6-month chemotherapy, an investigation of the minimum period of chemotherapy needed to achieve the complete prevention of TB reactivation is required using a time-titration approach. Furthermore, it must be determined whether a more effective therapeutic activity is possible, when a stronger immunotherapy than DNA vaccine is combined with a shortened period of chemotherapy.
In summary, the present study demonstrates that DNA vaccination with Ag85A or IL-12N220L DNA during chemotherapy course could confer a protective effect against M. tuberculosis reactivation. We speculate, therefore, that this vaccine regimen when used prophylactically and therapeutically might be able to both prevent the establishment of a latent state and eliminate M. tuberculosis already established. Further study is needed to understand the mechanism of the synergism between chemotherapy and simultaneously combined IL-12N220L or Ag85A DNA vaccine in the control of M. tuberculosis infection. In addition, it would be interesting to investigate whether the combination of IL-12N220L and Ag85A DNA has a synergistic effect upon the prevention of M. tuberculosis reactivation.
Materials and methods
Mice
Specific pathogen-free female C57BL/6J mice of 5-6 weeks of age were purchased from Japan SLC, Inc. (Shijuoka, Japan), maintained under barrier conditions in a BL-3 biohazard animal room at Yonsei University Medical Research Center, and fed a sterile commercial mouse diet and water ad libitum.
Bacteria and antigens
M. tuberculosis H37Rv (ATCC27294) was grown as surface pellicles on Sauton medium for about 10 days. Surface pellicles were collected and disrupted with 3 mm glass beads by gentle vortexing. After clumps had settled down, the upper suspension was collected and aliquots were stored at -701C. After thawing, viable organisms were enumerated by plating serial dilutions on Middlebrook 7H11 agar (Difco, Detroit, MI, USA). To inoculate M. tuberculosis into mice, bacterial suspensions were sonicated briefly and diluted with PBS to achieve the desired numbers. CF protein was kindly provided by JT Belisle (Colorado State University, Fort Collins, CO, USA). Recombinant Ag85A protein of M. tuberculosis was purchased commercially (Standardia Inc., Suwon, Korea).
IL-12N220L DNA constructs
The IL-12 DNA construct was prepared as described previously. 26 Briefly, pGX10, DNA vaccine vector, was generated by replacing the ampicillin resistance gene of pTV2 46 with the kanamycin resistance gene. pGX10 is composed of a CMV promoter, TPL, simian virus 40 (SV40) late polyA tail, and an SV40 enhancer, linked in tandem. Murine IL-12p35 (mp35), the internal ribosomal entry site (IRES) of encephalomyocarditis virus (EMCV), and murine IL-12p40 (mp40) cDNAs were also linked in a tandem, unidirectionally arranged and inserted into pGX10 vector, resulting in pGX10-mp35/IRES/mp40 (pGX10-IL-12). For the generation of mp40-N220L construct, asparagines residue at Asn220 of mp40, Nglycosylation site of mp40, was substituted with leucine residue by site-directed mutagenesis using PCR, as described previously. 26 The region of mp40 in pGX10-IL-12 was replaced with mp40-N220L to generate the murine IL-12 mutant construct, pGX10-mp35/IRES/ mp40-N220L (pGX10-IL-12N220L).
Ag85A DNA vaccine
To construct an efficient TB DNA vaccine vector, the signal sequence of herpes simplex virus type 1 glycoprotein D (gD) was fused with the Ag85A gene, and the fusion cassette was then inserted into the pGX10 vector resulting in a pGX10-Ag85A vaccine. Expression of the DNA vaccines against tuberculosis S-J Ha et al Ag85A gene was confirmed by radioimmunoprecipitation assay with mouse anti-Ag85A serum following the transfection of pGX10-Ag85A DNA into COS7 cells.
Latent infection model (modified Cornell model)
The Cornell model described by McCune et al 27 was employed with minor modification. Briefly, mice were exposed to a predetermined dose of M. tuberculosis H37Rv for 60 min in the inhalation chamber of an airborne infection apparatus (Glas-Col, Terre Haute, IN, USA). Bacteria were counted 1 day after exposure, and approximately 200 viable M. tuberculosis were found to have been delivered to the lungs. Mice were then treated with INH at 25 mg/kg/day and PZA at 1000 mg/kg/ day, in diet for 3 months, starting 4 weeks after aerosol infection. Bacterial counts were taken from the lungs and spleens of mice at 2 weeks after the completion of 3-month chemotherapy to confirm the clearance of cultivable organisms.
Immunotherapy with DNA vaccines
During the course of the latent infection model experiment described above, pGX10, pGX10-IL-12N220L, or pGX10-Ag85A DNA constructs of 50 mg were intramuscularly administered to mice three times at 4 weeks intervals during the course of INH and PZA treatment. Viable bacteria in tissues from mice were counted at 14 and 26 weeks after the completion of treatment, as described above.
Bacterial counts
Mice were euthanized with CO 2 , and lungs and spleens were homogenized in 0.04% Tween 80 saline. The tissue suspension was diluted 10-fold, and 100 ml of each dilution was plated in duplicate onto M7H11 agar plates and incubated at 371C for 3-4 weeks. M. tuberculosis colonies on each plate were enumerated and the results are expressed as log 10 CFU per organ.
IFN-g production
Spleen cells were prepared from mice, and 2 Â 10 5 lymphocytes were cultured in 200 ml of RPMI in the presence of CF or Ag85A protein at a concentration of 10 mg/ml for 6 days. Culture supernatant was then collected and used for detecting IFN-g, which was determined using a mouse IFN-g OptEIA TM kit (Pharmingen, San Diego, CA, USA) by following the procedure provided by the manufacturer.
Histopathology
For histopathological examination, organs were fixed in 10% buffered formalin and paraffin-embedded at different times. From the paraffin-embedded tissue blocks, 2-to 3-mm sections were prepared and stained with hematoxylin and eosin.
Statistical analysis
Data are expressed as the means of individual determinants and standard deviations (s.d.s). Statistical significance between the treatment groups was calculated using either the Student's t-test or the w 2 test, and a P-value of o0.05 was considered significant.
